

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n.1 posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale 06/D4 - Malattie Cutanee, Malattie Infettive e Malattie dell'Apparato Digerente, settore scientifico-disciplinare MED/17 - Malattie Infettive presso il Dipartimento di FISIOPATOLOGIA MEDICO-CHIRURGICA E DEI TRAPIANTI, (avviso bando pubblicato sulla G.U. n. 68 del 01/09/2020) Codice concorso 4447

[Andrea Lombardi] CURRICULUM VITAE

INFORMAZIONI PERSONALI

COGNOME	LOMBARDI
NOME	ANDREA
DATA DI NASCITA	12/01/1989

ESPERIENZA PROFESSIONALE

22/01/2010-in corso Medico Specialista in Malattie Infettive e Tropicali

UOC Malattie Infettive e Tropicali Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

- Attività di consulenza in dipartimenti medici e chirurgici
- Ambulatorio di Malattie Infettive generale e specialistico
- Sviluppo di progetti di ricerca traslazionale

01/11/2015-09/10/2019 Specializzando in Malattie Infettive e Tropicali

Università degli Studi di Pavia, Pavia (Italy)

- Gestione pazienti ricoverati con patologie infettive ad elevato grado di complessità
- Gestione ambulatoriale del paziente con infezione da HIV
- Gestione ambulatoriale del paziente con epatopatie virali
- Gestione ambulatoriale del paziente con epatopatie avanzate
- Attività di consulenza con implementazione programmi di stewardship antimicrobica in dipartimenti medici e chirurgici

01/06/2015-02/04/2016 Ricercatore

Université de Genève, Genève (Svizzera)

- Sviluppo del progetto: "*Alteration of the PTEN signalling network as a predictor of the development of metabolic liver disorders and hepatocellular carcinoma in chronic hepatitis C*". Attività di ricerca con esecuzione di Western-blot, colorazioni

immunoistochimiche, colture cellulari, citofluorimetria.

ISTRUZIONE E FORMAZIONE

01/09/2008-30/09/2014 Laurea in Medicina e Chirurgia

Università degli Studi di Pavia, Pavia (Italia)

Magna cum laude ed encomio.

01/11/2015-09/10/2019 Specializzazione in Malattie Infettive e Tropicali

Università degli Studi di Pavia, Pavia (Italia)

50/50 e lode

COMPETENZE PERSONALI

Lingua madre italiano

Lingue straniere

	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C1	C2	C1	C1	C1
francese	B2	B2	B2	B2	B2
IELTS certification overall band 7.5 (Writing 7, Speaking 7, Listening 7.5, Reading 8.5)					

ULTERIORI INFORMAZIONI

Riconoscimenti e premi

- Vincitore Fellowship Nuovo-Soldati Foundation for cancer research 2015 (<http://nuovosoldati.ch/projets15-16.php#LOMBARDI>)
- Presidente eletto del European Society of Clinical Microbiology and Infectious Disease (ESCMID) Study Group for Viral Hepatitis (ESGVH)

Pubblicazioni

Full papers

- Alagna L, Palomba E, Mangioni D, Bozzi G, Lombardi A et al. Multidrug-Resistant Gram-Negative Bacteria Decolonization in Immunocompromised Patients : A Focus on Fecal Microbiota Transplantation. International journal of molecular and cellular medicine (2020)
- Bandera et al. COVID-19 network: the response of an Italian reference Institute to research challenges about a new pandemia. Clin Microbiol Infect. (2020)
- Lombardi A et al. Characteristics of 1,573 Healthcare Workers Who Underwent Nasopharyngeal Swab for SARS-CoV-2 in Milano, Lombardy, Italy. Clin Microbiol Infect. (2020)
- Mondelli MU, Lombardi A, Colombo M. Hepatocellular carcinoma and hepatitis C virus: which should be treated first?. Clinical Dilemmas in Viral Liver Disease. (2020)
- Mele D, Oliviero B, Mantovani S, Ludovisi S, Lombardi A et al. Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients. Hepatology (2020)
- Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, Ossola M, Lombardi A et al. Pulmonary embolism in a young pregnant woman with Covid-19. Thrombosis Research

(2020)

- Villa S*, Lombardi A* et al. The COVID-19 pandemic preparedness or lack thereof: from China to Italy. *Global Health & Medicine* (2020)
- Lombardi A et al. Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a question needing an answer. *Journal of Hospital Infection* (2020)
- Maticic M, Lombardi A et al. Hepatitis V. Elimination of hepatitis C in Europe: can WHO targets be achieved? *Clin Microbiol Infect* (2020)
- Seminari E, Monzillo V, Lombardi A, et al. Migrations do not modify *Mycobacterium tuberculosis* resistance rates : a 20-year retrospective study. *Eur J Clin Microbiol Infect Dis* (2020)
- Zuccaro V, Lombardi A et al. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment? *Expert Opin Drug Metab Toxicol* (2020)
- Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, et al. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicenter cohort. *Liver Int* (2020)
- Fabbiani M, Cattaneo D, Lombardi A et al. Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. *J. Antimicrob. Chemother* (2020)
- Lombardi A, Rossotti R, Rockstroh JK et al. The use of intrahepatic portosystemic shunt in HIV positive patients: a retrospective multicentric study. *Dig Liv Dis* (2019)
- D'Ambrosio R, Pasulo L, Giorgini A et al. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. *Dig Liv Dis* (2019)
- Degasperis E, Spinetti A, Lombardi A, et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. *J Hepatol* (2019)
- Lombardi A, Mondelli MU. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. *Alimentary Pharmacology & Therapeutics* (2019)
- Zuccaro V, Lombardi A, Asperges E, Sacchi P, Marone P, Gazzola A, et al. The Possible Role of Gut Microbiota and Microbial Translocation Profiling During Chemo-Free Treatment of Lymphoid Malignancies. *Int J Mol Sci* (2019)
- Lombardi A, Zuccaro V, Vecchia M, Grecchi C, Patruno SFA et al. The impact of HIV infection and MSM status on hepatitis A infection: the experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period. *J Viral Hepat* (2019)
- Lombardi A, Mondelli MU, Bruno R. RE: Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. *Gastroenterology* (2019)
- Lombardi A, Zuccaro V, Fagiuoli S, et al. Prophylaxis of spontaneous bacterial peritonitis: Is there still room for quinolones? *J Hepatol* (2019)
- Vecchia M, Lombardi A, Zuccaro V, et al. A clinical case of sepsis due to *Staphylococcus pettenkoferi*. *Le Infez Med* (2018)
- Marcellusi A, Viti R, Kondili LA, et al. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. *Pharmacoeconomics* (2018)
- Lombardi A, Mondelli MU. Hepatitis C: is eradication possible? *Liver Int* (2018)
- Mantovani S, Oliviero B, Lombardi A, et al. Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma. *Hepatology*. (2018)
- Mele D, Mantovani S, Oliviero B, Grossi G, Lombardi A, et al. Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells. *J Hepatol* (2017)
- Lombardi A, Morbini P, Zuccaro V. & Bruno R. Impact of HBV and *S. mansoni* on portal

pressure: Synergy or innocent bystanders? *Liver Int.* (2017).

- Lombardi A, Croci GA, Brazzelli V, Vecchia M, Zuccaro V, Sciarra M and Bruno R. (2017), Cutaneous septic emboli from *Candida glabrata* in a haematological patient. *Am. J. Hematol.* (2017).

- Mariani M, Zuccaro V, Patruno SFA, Scudeller L, Sacchi P, Lombardi A et al. The impact of rifaximin in the prevention of bacterial infections in cirrhosis. *European Review for Medical and Pharmacological Sciences.* (2017).

- Lombardi A, Landonio S, Magni C, Cheli S, Mazzali C, Mondelli MU, et al. ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. *Pharmacology.* (2015)

- Varchetta S, Mele D, Lombardi A et al. Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. *Gut* (2015).

Chapters/books

- Mondelli MU, Lombardi A, Colombo M Hepatocellular carcinoma and hepatitis C virus: which should be treated first? *Clinical Dilemmas in Viral Liver Disease*, Second Edition (2020)

- Lombardi A, Mondelli MU. Chapter: "New therapies against the HBV virus." in "Hepatitis Viricas" 1st edition by Elsevier-Spain. (March 2016)

- Lombardi A, Mondelli MU. Chapter: "Hepatitis C: new antiviral drugs." in "Farmacia news" by Tecniche Nuove Editore (April 2016)

Abstracts

- Pasulo L, Gambato M, Spinetti A, D'Ambrosio R, Puoti M, Ciancio A, et al. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy. *Dig Liver Dis* (2019).

- Degasperi E, Spinetti A, Lombardi A, et al. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks. *Dig Liver Dis* (2019)

- Soria A, Lapadula G, Colella E, et al. THU-180-Treatment of genotype 3 HCV infection in the large real-life "Navigatore Lombardia" multicentre cohort: Results from three different regimens. *J Hepatol.* (2019)

- Pasulo L, Gambato M, Spinetti A, et al. THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. *J Hepatol* (2019)

- Pasulo L, Gambato M, Spinetti A, et al. P592 Treatment of Genotype 3 Cirrhotic Patients with 12 Weeks Sofosbuvir/Velpatasvir with or without Ribavirin: Real Life Experience from Italy. *Hepatology* (2018)

- Varchetta S, Mele D, Lombardi A, Leoni MC, Spreafico M, Prati D, et al. Role of sialic-acid-binding immunoglobulin-like lectin-7 (siglec-7) as biomarker of liver disease severity in chronic HCV infection. *Dig Liver Dis* (2014)

- Varchetta S, Mele D, Lombardi A, Leoni MC, Spreafico M, Prati D, et al. P125 Role of Sialic-Acid-Binding Immunoglobulin-Like Lectin-7 (Siglec-7) As Biomarker of Liver Disease

Severity in Chronic HCV Infection. J Hepatol (2014)

Reviewer per le seguenti riviste:

- Clinical Infectious Diseases
- Liver International
- Digestive and Liver Disease

Presentazioni

- AISF 2019 (Roma)
- ECCMID 2019 (Amsterdam)
- ICAR 2019 (Milano)
- CO-INFECTION WORKSHOP 2018 (Siviglia)

Corsi

- Insegnamento modulo "Immune Exhaustion in infectious diseases" al IX Master Universitario di II livello in Immunopatologia dell'età evolutiva edizione A.A. 2018/2019 (Pavia, Italy)
- Lecture "New therapeutic approaches towards HBV elimination", ESCMID PGC "Viral hepatitis elimination: are we ready?" 27-28/09/2019 (Ljubljana, Slovenia)

Appartenenza a gruppi/associazioni

Membro delle seguenti società scientifiche:

- ESCMID (European Society of Clinical Microbiology and Infectious Diseases)
- SIMIT (Società Italiana di Malattie Infettive e Tropicali)
- SITA 8 (Società Italiana Terapia Antinfettiva)
- EASL (The European Association for the Study of the Liver)
- AISF (Associazione Italiana per lo Studio del Fegato)

Data

14/09/2020

Luogo

Milano